A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda

被引：0
|
作者：
Solomon J. Lubinga
Byamah B. Mutamba
Angelo Nganizi
Joseph B. Babigumira
机构：
[1] University of Washington,Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy
[2] University of Washington,Global Medicines Program, Department of Global Health
[3] Butabika National Referral Hospital for Mental,undefined
[4] Neurological and Substance Abuse Disorders,undefined
[5] Kadic Hospital,undefined
来源：
Applied Health Economics and Health Policy | 2015年 / 13卷
关键词：
Schizophrenia; Haloperidol; Risperidone; Olanzapine; Quetiapine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：493 / 506
页数：13
相关论文
共 50 条
  • [21] Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis
    Diana De Graeve
    Ann Smet
    Angelika Mehnert
    Sue Caleo
    Houda Miadi-Fargier
    Guillermo Jasso Mosqueda
    Damien Lecompte
    Joseph Peuskens
    PharmacoEconomics, 2005, 23 : 35 - 47
  • [22] Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK
    Tempest, Michael
    Sapin, Christophe
    Beillat, Maud
    Robinson, Paul
    Treur, Maarten
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2015, 18 (04): : 185 - 200
  • [23] Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria
    Ignatova, Desislava
    Kamusheva, Maria
    Petrova, Guenka
    Onchev, Georgi
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2019, 33 (01) : 204 - 213
  • [24] Assessing cost-effectiveness of drug interventions for schizophrenia
    Magnus, A
    Carr, V
    Mihalopoulos, C
    Carter, R
    Vos, T
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2005, 39 (1-2): : 44 - 54
  • [25] Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
    Hong Liu-Seifert
    Haya Ascher-Svanum
    Olawale Osuntokun
    Kai Yu Jen
    Juan Carlos Gomez
    BMC Psychiatry, 11
  • [26] The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: A systematic review of economic evaluations
    Achilla E.
    McCrone P.
    Applied Health Economics and Health Policy, 2013, 11 (2) : 95 - 106
  • [27] COST-EFFECTIVENESS OF CLOZAPINE TREATMENT IN THERAPY-REFRACTORY SCHIZOPHRENIA
    JONSSON, D
    WALINDER, J
    ACTA PSYCHIATRICA SCANDINAVICA, 1995, 92 (03) : 199 - 201
  • [28] Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China
    Yi, Zhan-Miao
    Men, Peng
    Qu, Shuli
    Li, Chaoyun
    Yu, Xin
    Zhai, Suodi
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (03) : 313 - 320
  • [29] Cost-effectiveness model of long-acting risperidone in schizophrenia in the US
    Natalie C. Edwards
    Marcia F. T. Rupnow
    Chris L. Pashos
    Marc F. Botteman
    Ronald J. Diamond
    PharmacoEconomics, 2005, 23 : 299 - 314
  • [30] Cost-effectiveness and Price of Aripiprazole for Schizophrenia in the Brazilian Public Health System
    Santos, Andre Soares
    Micaela de Souza Noronha, Kenya Valeria
    Andrade, Monica Viegas
    Ruas, Cristina Mariano
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2020, 23 (01): : 27 - 37
12345